Revance Releases Third Quarter 2016 Results
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the third quarter ended September 30, 2016.
Recent Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection (RT002)
• Initiated the Phase 3 program for RT002 to treat glabellar (frown) lines and expects to dose the first patient this quarter. Revance plans to report topline results in the fourth quarter of 2017.
Recent Highlights and Upcoming Milestones for DaxibotulinumtoxinA for Injection (RT002)
• Initiated the Phase 3 program for RT002 to treat glabellar (frown) lines and expects to dose the first patient this quarter. Revance plans to report topline results in the fourth quarter of 2017.